{"id":757102,"date":"2023-05-10T05:04:14","date_gmt":"2023-05-10T09:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/"},"modified":"2023-05-10T05:04:14","modified_gmt":"2023-05-10T09:04:14","slug":"alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/","title":{"rendered":"Alvotech enters into commercialization agreement with Polifarma  for proposed biosimilar to Eylea\u00ae (aflibercept)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Polifarma will commercialize AVT06, a proposed biosimilar to Eylea<sup>\u00ae<\/sup> (aflibercept), in Turkey<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>REYKJAVIK, Iceland, May  10, 2023  (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. (\u201cPolifarma\u201d) for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea<sup>\u00ae<\/sup> (aflibercept).<\/p>\n<p>\u201cIt is a pleasure to join forces with Polifarma in the commercialization of a potential therapy in eye disease,\u201d said Robert Wessman, Chairman and CEO of Alvotech. \u201cWe are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and important Turkish market.\u201d<\/p>\n<p>&#8220;Polifarma has been contributing to public health and the health sector in the world for 37 years with its motto of &#8216;We stand by life&#8217;. This agreement with Alvotech allows us to expand our portfolio and further strengthen our position in the ophthalmology area. We are excited to have the opportunity to commercialize this product in Turkey,&#8221; said Mehmet Asri, CEO of Polifarma.<\/p>\n<p>According to the agreement, Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization.<\/p>\n<p>AVT06 is a biosimilar candidate currently in clinical development. In <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wIlVFT1oNgSVszZoaBk6qh3nOptOFNispIu8STGBY_4ALrt_7UBfZFCh8KaHpWJqfT2GVzROMmRfmuTLNQhscaoQEaubkBLLzW6l2XPgQZm8bMJUtOyVXGftSFabMv6akVR1IvAHuEYGtKA45vpvIAow1byha8zw5bh732VPmrzQD4NX6sIKw91wj5PGUP1Y8UV2n6JoV3G-vNJVt3xsFA==\" rel=\"nofollow noopener\" target=\"_blank\">July 2022<\/a>, Alvotech announced the initiation of a patient study to compare AVT06 and Eylea<sup>\u00ae<\/sup> in terms of efficacy, safety, and immunogenicity in adult patients with neovascular (wet) age-related macular degeneration (AMD).<\/p>\n<p>\n        <strong>About AVT06 <\/strong><br \/>\n        <br \/>AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea<sup>\u00ae<\/sup> (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability. AVT06 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.<\/p>\n<p>\n        <strong>About Polifarma<\/strong><br \/>\n        <br \/>Polifarma is the market leader of hospital products in Turkey and has a 37-year history, with 100% domestic capital. While developing its IV drug portfolio, Polifarma started to grow in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p246WFWaWF0G0sFSvlrzB22xFrxZCgIA9Nxqs3JMsse6NRKbazW3z4gKExx_4K8nV8LBfy8K4uTVrOssXNX2TConJsET5r2t55NFqfAEURP4tVEGsIM9jMlJ8CWsEy5-\" rel=\"nofollow noopener\" target=\"_blank\">prescribed<\/a> markets. As a leading brand in the Turkish health sector, Polifarma produces 350 million boxes per year at its 77 thousand square meter facility in Ergene\/Tekirda\u011f. Besides manufacturing ampoules, vials and pre-filled syringes (PFS), Polifarma has 600 licensed products in all forms and 12 certificates in 15 therapeutic areas. Polifarma offers innovative solutions, such as Turkey&#8217;s first lipid product and the world&#8217;s first three-chamber parenteral nutrition solution and CAPD device. Exporting to 70 countries, Polifarma&#8217;s vision is to become a global leader by 2025 and maintain its position with EU-GMP compliance and a commitment to quality and technology.<\/p>\n<p>\n        <strong>About Alvotech<\/strong><br \/>\n        <br \/>Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech\u2019s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech\u2019s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla\/Cipla Gulf\/Cipla Med Pro (Australia, New Zealand, South Africa\/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ums8kxBnt3vEgI39-h-PprXwS7Ys8pi6ogwfSjCdpVLD3ZjMtnWaIANXkxbo3zrSCrgULlttPY2PNlWTlxWQJg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.alvotech.com<\/u><\/a>. None of the information on the Alvotech website shall be deemed part of this press release.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this communication may be considered \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech\u2019s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the satisfactory responses to the FDA\u2019s inspection findings and resolution of other deficiencies conveyed following the inspection of Alvotech\u2019s manufacturing site, the potential approval and commercial launch of its product candidates, the timing of regulatory approval and market launches, and the estimated size of the total addressable market of Alvotech\u2019s pipeline products. In some cases, you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cpredict\u201d, \u201cpotential\u201d, \u201caim\u201d or \u201ccontinue\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech\u2019s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and\/or competitive factors; (5) Alvotech\u2019s estimates of expenses and profitability; (6) Alvotech\u2019s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech\u2019s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech\u2019s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech\u2019s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech\u2019s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech\u2019s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech\u2019s products and product candidates; (17) the potential impact of the ongoing COVID-19 pandemic on regulatory review timelines, including the ability to complete timely inspection of manufacturing sites; (18) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company\u2019s business, financial position, strategy and anticipated milestones; and (19) other risks and uncertainties set forth in the sections entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.<\/p>\n<p>\n        <strong>CONTACTS<\/strong><br \/>\n        <br \/>\n        <strong>Alvotech Investor Relations and Global Communications<\/strong><br \/>\n        <br \/>Benedikt Stefansson<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TNWHabwM1y8s32T5knT-bg349wqX-C1OjSKyAO6AK42m4qngX5X0n01e3klBpj_kvo5rM1KBl_LuGSHPfVUkyyK0C_Hfu3JkKCL13hzYucCqAhelzpSwT9MGXsd-d3Nk\" rel=\"nofollow noopener\" target=\"_blank\"><u>alvotech.ir[at]alvotech.com<\/u><\/a><\/p>\n<p>\n        <strong>Polifarma Corporate Communications and Marketing Manager<\/strong><br \/>\n        <br \/>Sevda Karasu<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H4ENdw0OMGiO9hOrCSBr88ar2sz1Bw1i7DtwQG95J3zetV6KnXmz7r6Qa_vezJPCRPIOz6xX34J4KQz9rWz1nnRxcd955n2Iy1XsAv1xYWJIbWjt7yAoI1IGsFsHZfIA\" rel=\"nofollow noopener\" target=\"_blank\">sevdakarasu@polifarma.com.tr<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YjVjMWJhMTItZTIzNi00MjczLWIzNTYtYWEyNGUyM2NmNTk0LTEyNDUzODY=\/tiny\/Alvotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Polifarma will commercialize AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. (\u201cPolifarma\u201d) for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept). \u201cIt is a pleasure to join forces with Polifarma in the commercialization of a potential therapy in eye disease,\u201d said Robert Wessman, Chairman and CEO of Alvotech. \u201cWe are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alvotech enters into commercialization agreement with Polifarma  for proposed biosimilar to Eylea\u00ae (aflibercept)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-757102","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Polifarma will commercialize AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. (\u201cPolifarma\u201d) for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept). \u201cIt is a pleasure to join forces with Polifarma in the commercialization of a potential therapy in eye disease,\u201d said Robert Wessman, Chairman and CEO of Alvotech. \u201cWe are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and &hellip; Continue reading &quot;Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T09:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)\",\"datePublished\":\"2023-05-10T09:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/\"},\"wordCount\":1587,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/\",\"name\":\"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\",\"datePublished\":\"2023-05-10T09:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/","og_locale":"en_US","og_type":"article","og_title":"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk","og_description":"Polifarma will commercialize AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept), in Turkey REYKJAVIK, Iceland, May 10, 2023 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. (\u201cPolifarma\u201d) for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea\u00ae (aflibercept). \u201cIt is a pleasure to join forces with Polifarma in the commercialization of a potential therapy in eye disease,\u201d said Robert Wessman, Chairman and CEO of Alvotech. \u201cWe are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and &hellip; Continue reading \"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-10T09:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)","datePublished":"2023-05-10T09:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/"},"wordCount":1587,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/","name":"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==","datePublished":"2023-05-10T09:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwOTA2NiM0MDE1NDAyNjgjMjIzMzgzMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea\u00ae (aflibercept)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=757102"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757102\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=757102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=757102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=757102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}